 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Kidney Disease in Patients with Lupus Who Are Treated with Potent Drugs that Suppress the Immune System
21 August 2001 | Volume 135 Issue 4 | Page S29
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis." It is in the 21 August 2001 issue of Annals of Internal Medicine (volume 135, pages 248-257). The authors are GG Illei, HA Austin III, M Crane, L Collins, MF Gourley, CH Yarboro, EM Vaughan, T Kuroiwa, CL Danning, AD Steinberg, JH Klippel, JE Balow, and DT Boumpas.
What is the problem and what is known about it so far?
Lupus is a disease of the immune system that can damage many body organs. Damage to the kidneys from this disease is known as lupus nephritis. Lupus nephritis is difficult to treat and can return even if initial treatment is successful. If left untreated, lupus nephritis can progress to complete kidney failure. Patients with kidney failure need kidney transplantation or hemodialysis (a procedure in which a special machine filters the blood). Treatment of lupus nephritis often includes two powerful drugs that suppress the immune system: methylprednisolone and cyclophosphamide. Both of these drugs can have serious side effects. An earlier study showed that cyclophosphamide, either alone or in combination with methylprednisolone, was more effective than methylprednisolone alone in the short term (< 5 years). At the end of 5 years, patients who received the combination seemed to do better than the other groups, but these results were not clear cut. It is not known what happens after 5 years to patients treated with these drugs.
Why did the researchers do this particular study?
To find out whether patients with lupus nephritis do best in the long term (beyond 5 years) if they are treated with cyclophosphamide alone, methylprednisolone alone, or a combination of the two drugs.
Who was studied?
The researchers studied 82 patients with lupus nephritis who participated in a 1986–1990 study comparing the effects of treatment with cyclophosphamide alone, methylprednisolone alone, and the two drugs in combination.
How was the study done?
The researchers followed the patients from the time they enrolled in the study through August 1999. They collected information on whether treatment failed (defined as blood tests that showed worsening kidney function, the need for additional drugs to treat the lupus nephritis, or death) and whether serious side effects of the drugs occurred.
What did the researchers find?
Treatment was less likely to fail in patients who were initially treated with cyclophosphamide, alone or in combination with methylprednisolone, than in patients initially treated with methylprednisolone alone. Among patients who completed their original treatment, the rate of worsening kidney function was lower in those who took cyclophosphamide plus methylprednisolone. Similar numbers of side effects occurred in all three groups.
What were the limitations of the study?
Many of the patients changed treatment during the study, so the results are not as definitive as they might be. Some experts believe it would have been better if the researchers looked for development of kidney failure as the main outcome.
What are the implications of the study?
Over the long term, patients with lupus nephritis who receive cyclophosphamide, either alone or in combination with methylprednisolone, appear to do better than patients treated with methylprednisolone alone. Adding methylprednisolone to cyclophosphamide therapy appears to provide more benefit than cyclophosphamide alone but does not increase the patient's risk for adverse events.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al. Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]
|
|
|
|
 |
|
 L. F, T. Y, P. X, W. L, W. H, S. Z, Z. H, and H. Z A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis Lupus, July 1, 2008; 17(7): 622 - 629. [Abstract] [PDF]
|
|
|
|
|
|
G Bertsias, C Gordon, and D. Boumpas Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials Lupus, May 1, 2008; 17(5): 437 - 442. [Abstract] [PDF]
|
|
|
|
|
|
W. F. Clark and J. M. Sontrop What Have We Learned about Optimal Induction Therapy for Lupus Nephritis (III through V) from Randomized, Controlled Trials? Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 895 - 898. [Full Text] [PDF]
|
|
|
|
|
|
G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Contreras and J. Sosnov Role of Mycophenolate Mofetil in the Treatment of Lupus Nephritis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 879 - 882. [Full Text] [PDF]
|
|
|
|
|
|
B. Ranchin and S. Fargue Review: New treatment strategies for proliferative lupus nephritis: keep children in mind! Lupus, August 1, 2007; 16(8): 684 - 691. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis Rheumatology, July 1, 2007; 46(7): 1096 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Parker and I. Bruce High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 387 - 393. [Abstract] [PDF]
|
|
|
|
|
|
S. A. Chambers, A. Rahman, and D. A. Isenberg Treatment adherence and clinical outcome in systemic lupus erythematosus Rheumatology, June 1, 2007; 46(6): 895 - 898. [Full Text] [PDF]
|
|
|
|
|
|
G. G. Illei, C. H. Yarboro, T. Kuroiwa, R. Schlimgen, H. A. Austin, J. F. Tisdale, P. Chitkara, T. Fleisher, J. H. Klippel, J. E. Balow, et al. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis Rheumatology, June 1, 2007; 46(6): 952 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Houssiau Thirty years of cyclophosphamide: assessing the evidence Lupus, March 1, 2007; 16(3): 212 - 216. [Abstract] [PDF]
|
|
|
|
|
|
D Jayne Current management of lupus nephritis: popular misconceptions Lupus, March 1, 2007; 16(3): 217 - 220. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]
|
|
|
|
|
|
C Flower, A Hennis, I R Hambleton, and G Nicholson Lupus nephritis in an Afro-Caribbean population: renal indices and clinical outcomes Lupus, October 1, 2006; 15(10): 689 - 694. [Abstract] [PDF]
|
|
|
|
|
|
G Ruiz-Irastorza, M-V Egurbide, J-I Pijoan, M Garmendia, I Villar, A Martinez-Berriotxoa, J-G Erdozain, and C Aguirre Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 577 - 583. [Abstract] [PDF]
|
|
|
|
|
|
X Bosch, A Guilabert, L Pallares, R Cervera, M Ramos-Casals, A Bove, M Ingelmo, and J Font Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients Lupus, September 1, 2006; 15(9): 584 - 589. [Abstract] [PDF]
|
|
|
|
|
|
G. Moroni, A. Doria, M. Mosca, O. D. C. Alberighi, G. Ferraccioli, S. Todesco, C. Manno, P. Altieri, R. Ferrara, S. Greco, et al. A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 925 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Bihl, M. Petri, and D. M. Fine Kidney biopsy in lupus nephritis: look before you leap Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1749 - 1752. [Full Text] [PDF]
|
|
|
|
|
|
C. Ponticelli New Therapies for Lupus Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 863 - 868. [Full Text] [PDF]
|
|
|
|
|
|
K C Tse, C S. Tang, W I Lio, M F Lam, and T M Chan Quality of life comparison between corticosteroidand-mycofenolate mofetil and corticosteroidand-oral cyclophosphamide in the treatment of severe lupus nephritis Lupus, June 1, 2006; 15(6): 371 - 379. [Abstract] [PDF]
|
|
|
|
|
|
C E. Barber, L Geldenhuys, and J G Hanly Sustained remission of lupus nephritis Lupus, February 1, 2006; 15(2): 94 - 101. [Abstract] [PDF]
|
|
|
|
 |
|
 W. J. McCune Mycophenolate Mofetil for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2282 - 2284. [Full Text] [PDF]
|
|
|
|
|
|
G H Stummvoll, M Aringer, J S Smolen, S Schmaldienst, E Jimenez-Boj, W H Horl, W B Graninger, and K Derfler IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study Ann Rheum Dis, July 1, 2005; 64(7): 1015 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Fine Pharmacological Therapy of Lupus Nephritis JAMA, June 22, 2005; 293(24): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T M Chan, K C Tse, C S. Tang, K N Lai, and F K Li Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine Lupus, April 1, 2005; 14(4): 265 - 272. [Abstract] [PDF]
|
|
|
|
|
|
T M Chan Lupus nephritis: induction therapy Lupus, March 1, 2005; 14(3_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
C. Gorman, A. Bhatia, and A. Rahman This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis Rheumatology, March 1, 2005; 44(3): 398 - 401. [Full Text] [PDF]
|
|
|
|
|
|
C C Mok Prognostic factors in lupus nephritis Lupus, January 1, 2005; 14(1): 39 - 44. [Abstract] [PDF]
|
|
|
|
|
|
F A Houssiau Cyclophosphamide in lupus nephritis Lupus, January 1, 2005; 14(1): 53 - 58. [Abstract] [PDF]
|
|
|
|
|
|
T. Chan Lupus nephritis: induction therapy Lupus, January 1, 2005; 14(1_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
C. P. Mavragani, P. G. Vlachoyiannopoulos, N. Kosmas, I. Boletis, A. G. Tzioufas, and M. Voulgarelis A case of reversible posterior leucoencephalopathy syndrome after rituximab infusion Rheumatology, November 1, 2004; 43(11): 1450 - 1451. [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Houssiau Management of Lupus Nephritis: An Update J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2694 - 2704. [Full Text] [PDF]
|
|
|
|
|
|
G E Katsifis and A G Tzioufas Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide Lupus, September 1, 2004; 13(9): 673 - 678. [Abstract] [PDF]
|
|
|
|
|
|
M-C Park, Y-B Park, S Y Jung, I H Chung, K H Choi, and S-K Lee Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy Lupus, August 1, 2004; 13(8): 569 - 574. [Abstract] [PDF]
|
|
|
|
|
|
G Haugeberg, B Griffiths, K B Sokoll, and P Emery Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study Ann Rheum Dis, August 1, 2004; 63(8): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Vasoo First international meeting on mycophenolate mofetil: an advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK Lupus, July 1, 2004; 13(7): 543 - 545. [PDF]
|
|
|
|
|
|
M Petri Cyclophosphamide: new approaches for systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 366 - 371. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
|
|
J Schiffenbauer and L S Simon Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus, May 1, 2004; 13(5): 398 - 405. [Abstract] [PDF]
|
|
|
|
|
|
C-S Yee, C Gordon, C Dostal, P Petera, J Dadoniene, B Griffiths, B Rozman, D A Isenberg, G Sturfelt, O Nived, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis Ann Rheum Dis, May 1, 2004; 63(5): 525 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Gonzalez-Lopez, E G Cardona-Munoz, A Celis, I Garcia-de la Torre, G Orozco-Barocio, M Salazar-Paramo, C Garcia-Gonzalez, A Garcia-Gonzalez, A Sanchez-Ortiz, B Trujillo-Hernandez, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus Lupus, February 1, 2004; 13(2): 105 - 112. [Abstract] [PDF]
|
|
|
|
|
|
M El Hachmi, M Jadoul, C Lefebvre, G Depresseux, and F A Houssiau Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome Lupus, September 1, 2003; 12(9): 692 - 696. [Abstract] [PDF]
|
|
|
|
|
|
C C Mok and C S Lau Lupus in Hong Kong Chinese Lupus, September 1, 2003; 12(9): 717 - 722. [Abstract] [PDF]
|
|
|
|
|
|
C P Mavragani and H M Moutsopoulos Lupus nephritis: current issues Ann Rheum Dis, September 1, 2003; 62(9): 795 - 798. [Full Text] [PDF]
|
|
|
|
|
|
C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Stallmach, B M Wittig, C Moser, J Fischinger, R Duchmann, and M Zeitz Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease Gut, March 1, 2003; 52(3): 377 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Ioannou and D A Isenberg Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Postgrad. Med. J., October 1, 2002; 78(924): 599 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Spiera, P. Homel, and H. Spiera Long-Term Outcome in Lupus Nephritis Ann Intern Med, September 17, 2002; 137(6): 545 - 545. [Full Text] [PDF]
|
|
|
|
|
|
F. A. Houssiau and M. Jadoul Cytotoxic therapy of lupus nephritis: recent developments Nephrol. Dial. Transplant., June 1, 2002; 17(6): 955 - 957. [Full Text] [PDF]
|
|
|
|
|
|
Robin Goodfellow Rheumatology, January 1, 2002; 41(1): 118 - 118. [Full Text] [PDF]
|
|
|
|
|
|
E. J. Lewis The Treatment of Lupus Nephritis: Revisiting Galen Ann Intern Med, August 21, 2001; 135(4): 296 - 298. [Full Text] [PDF]
|
|
